Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing

BRISBANE, Calif. & BOSTON–(BUSINESS WIRE)–SANGAMO THERAPEUTICS AND CHROMA MEDICINE ANNOUNCE OPTION AND LICENSE AGREEMENT TO EVALUATE AND DEVELOP ZINC FINGER PROTEINS FOR EPIGENETIC EDITING
Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks